Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview | 11 | 1 |
| Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Comparative Analysis | 12 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics under Development by Companies | 13 | 2 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Products under Development by Companies | 19 | 2 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Products under Investigation by Universities/Institutes | 21 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Companies Involved in Therapeutics Development | 22 | 17 |
| Altor BioScience Corporation | 22 | 1 |
| APIM Therapeutics AS | 23 | 1 |
| Astellas Pharma Inc. | 24 | 1 |
| Bavarian Nordic A/S | 25 | 1 |
| BioCancell Ltd | 26 | 1 |
| Celgene Corporation | 27 | 1 |
| Cold Genesys, Inc. | 28 | 1 |
| F. Hoffmann-La Roche Ltd. | 29 | 1 |
| Heat Biologics, Inc. | 30 | 1 |
| Merck &Co., Inc. | 31 | 1 |
| Spectrum Pharmaceuticals, Inc. | 32 | 1 |
| Taris Biomedical LLC | 33 | 1 |
| UroGen Pharmaceuticals, Ltd. | 34 | 1 |
| Vakzine Projekt Management GmbH | 35 | 1 |
| Vaxiion Therapeutics, Inc. | 36 | 1 |
| Viralytics Ltd. | 37 | 1 |
| Viventia Bio Inc. | 38 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Assessment | 39 | 11 |
| Assessment by Monotherapy Products | 39 | 1 |
| Assessment by Target | 40 | 3 |
| Assessment by Mechanism of Action | 43 | 3 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 120 |
| ALT-801 Drug Profile | 50 | 2 |
| ALT-803 Drug Profile | 52 | 3 |
| apaziquone Drug Profile | 55 | 3 |
| atezolizumab Drug Profile | 58 | 13 |
| ATX-101 Drug Profile | 71 | 1 |
| BC-819 Drug Profile | 72 | 3 |
| Biologic for Superficial Bladder Cancer Drug Profile | 75 | 1 |
| cavatak Drug Profile | 76 | 11 |
| CG-0070 Drug Profile | 87 | 2 |
| CV-301 Drug Profile | 89 | 2 |
| DAB-389EGF Drug Profile | 91 | 1 |
| docetaxel Drug Profile | 92 | 1 |
| Drug for NMIBC Drug Profile | 93 | 1 |
| erlotinib hydrochloride Drug Profile | 94 | 4 |
| gemcitabine hydrochloride Drug Profile | 98 | 1 |
| imiquimod Drug Profile | 99 | 2 |
| lenalidomide Drug Profile | 101 | 15 |
| mitomycin SR Drug Profile | 116 | 1 |
| Monoclonal Antibody to Antagonize EGFR for Superficial Bladder Cancer Drug Profile | 117 | 1 |
| nitroxoline Drug Profile | 118 | 1 |
| P-MAPA Drug Profile | 119 | 2 |
| paclitaxel Drug Profile | 121 | 1 |
| pembrolizumab Drug Profile | 122 | 33 |
| rAd-IFN Drug Profile | 155 | 2 |
| sirolimus albumin-bound Drug Profile | 157 | 2 |
| Vaccine for Oncology Drug Profile | 159 | 1 |
| VAX-014 Drug Profile | 160 | 1 |
| VB-4845 Drug Profile | 161 | 2 |
| vesigenurtucel-L Drug Profile | 163 | 5 |
| VPM-1002 Drug Profile | 168 | 2 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Dormant Projects | 170 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Discontinued Products | 171 | 1 |
| Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Product Development Milestones | 172 | 9 |
| Featured News &Press Releases | 172 | 1 |
| Aug 10, 2016: TARIS Biomedical Launches Second Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Bladder Cancer | 172 | 1 |
| May 06, 2016: Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research (AUA) in San Diego, California, May 6-10, 2016 | 172 | 1 |
| May 05, 2016: UroGen Pharma Announces Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association s 2016 Annual Meeting | 173 | 1 |
| Apr 07, 2016: Heat Biologics Announces Cost-Saving Measures and Focused Corporate Strategy to Achieve Important Clinical Milestone | 174 | 1 |
| Feb 25, 2016: Heat Biologics Provides Update on Its HS-410 Phase II Monotherapy Bladder Cancer Trial Arm | 174 | 1 |
| Feb 19, 2016: Spectrum Pharmaceuticals Announces FDA Acceptance of NDA Filing for EOquin (apaziquone for intravesical instillation) | 174 | 1 |
| Feb 10, 2016: FDA Lifts Heat Biologics Partial Clinical Hold | 175 | 1 |
| Feb 03, 2016: Heat Biologics Reports Update on Its HS-410 Phase 2 Bladder Cancer Trial | 175 | 1 |
| Jan 26, 2016: Heat Biologics CSO to Present Interim Results From the Monotherapy Arm in Its Ongoing HS-410 Phase 2 Bladder Cancer Trial at the Phacilitate Immunotherapy World Conference | 175 | 1 |
| Jan 13, 2016: UroGen Pharma Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset | 176 | 1 |
| Nov 06, 2015: Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer Annual Meeting | 177 | 1 |
| Nov 03, 2015: Results of Heat Biologics' HS-410 Phase 1 Safety Trial in Non-Muscle Invasive Bladder Cancer to be Presented at SITC Annual Meeting | 178 | 1 |
| Oct 26, 2015: Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial for the Treatment of Non-Muscle Invasive Bladder Cancer Following SPA Agreement | 178 | 1 |
| Aug 17, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer | 179 | 1 |
| Jul 02, 2015: Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer | 180 | 1 |
| Appendix | 181 | 2 |
| Methodology | 181 | 1 |
| Coverage | 181 | 1 |
| Secondary Research | 181 | 1 |
| Primary Research | 181 | 1 |
| Expert Panel Validation | 181 | 1 |
| Contact Us | 181 | 1 |
| Disclaimer | 182 | 1 |